Therapeutic CBD

Relieves symptoms of the most grievous diseases

Healthy Living Magazine CBD

Healthy Living Magazine CBD

The social impediment that has been the roadblock before cannabidiol (CBD) research is the experience with THC (Δ9-tetrahydrocannabinol), another cannabinoid, the one that makes users “high”; although the body possesses different cannabinoid receptors (CB1 and CB2 among others), the inherent psychoactive properties of THC produce unwanted side effects by their action on the centrally located CB1 receptors.

Only since 1988 when Allyn Howlett and William Devane used radioimmunoassay testing with rat brains has science known of the organ’s cannabinoid receptors.

Read: Obama In Peace With Pot Users

In 1990 Miles Herkenham and co-investigators mapped out clusters of the receptor system in the areas of the human brain’s hippocampus and cerebellum indicating cannabinoids’ effects on cognition, mood and movement.

CBD is thought to have wide medical applications for mood, anxiety and movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis, epilepsy, spasticity, hepatic (alcoholic) encephalopathy, traumatic brain and spinal cord injury.

These prospects have “triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease,” says Pharmacological Reviews.

“The use of selective CB(2) receptor agonists, [such as CBD] which lack psychoactive properties, could represent another promising avenue for [multiple] conditions,” offer scientists.

Parkinson's Quality of Life

A study in the Journal of Psychopharmacology on 21 Parkinson’s disease (PD) patients used CBD, one of some 85 cannabinoids found in hemp, possessing therapeutic as opposed to psychoactive properties.

“Our findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives are required before definitive conclusions can be drawn.”

Alzheimer's Social Withdrawal

Long-term CBD treatment “prevents the development of [facial]recognition memory deficits in Alzheimer’s disease,” in AD transgenic mice, says the Journal of Alzheimer’s Disease.

These findings “provide the first evidence that CBD may have potential as a preventative treatment for AD with a particular relevance for symptoms of social withdrawal and facial recognition.”

Read: Colorado Court Hears Appeal Of Worker Fired For Medical Marijuana

Anti-Psychotic

CBD “can ameliorate positive and negative symptoms of schizophrenia. Behavioural and neurochemical models suggest that CBD has a pharmacological profile similar to that of atypical anti-psychotic drugs and a clinical trial reported that this cannabinoid is a well-tolerated alternative treatment for schizophrenia.”

FDA-Approved CBD

CBD is currently allowed for use under the Food and Drug Administration’s orphan drug law for Dravet syndrome and sold as Epidiolex.

In fact, the first patent for use of cannabinoids as neuroprotectors was issued in April 1999 and listed Aidan J. Hampson, Julius Axelrod and Maurizio Grimaldi, all of whom held positions at the National Institute of Mental Health, which is part of the National Institutes of Health, an agency of the United States Department of Health and Human Services.

On February 7, 2014 the president signed into law the 2013 Farm Bill. Section 7606 defined industrial hemp for agricultural use and authorized institutions of higher education or state departments of agriculture where hemp is legal to grow it for research or pilot programs.

The use of CBD in foods, such as chewing gums, delivers concentrated CBD from industrial hemp, supplying 10 milligrams per piece.

This patent-pending technology utilizes the mouth’s rich capillary bed for proprietary delivery mechanisms of cannabinoids to the central circulation, bypassing the gastrointestinal tract and liver degradation. Consult your doctor prior to using any CBD products.

REFERENCES Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, Dos Santos AC, Teixeira AL, Hallak JE, Crippa JA. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. J Psychopharmacol. 2014 Nov;28(11):1088-1098. doi: 10.1177/0269881114550355. E-pub 2014 Sept 18. Cheng D, Spiro AS, Jenner AM, Garner B, Karl T. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice. J Alzheimer’s Dis. 2014 Jan 1;42(4):1383-1396. doi: 10.3233/JAD-140921. Deiana S. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug Test Anal. 2013 Jan;5(1):46-51. doi: 10.1002/dta.1425. E-pub 2012 Oct 25. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 2006 Sept;58(3):389-462.
comments powered by Disqus